CAR-T cell therapy and infection: a review

被引：71

作者：

Bupha-Intr, Olivia ^{[1
]}

Haeusler, Gabrielle ^{[1
,2
,3
,4
]}

Chee, Lynette ^{[5
,6
,7
]}

Thursky, Karin ^{[1
,2
,7
]}

Slavin, Monica ^{[1
,2
,7
]}

Teh, Benjamin ^{[1
,2
,7
]}

机构：

[1] Peter MacCallum Canc Ctr, Dept Infect Dis, Melbourne, Vic, Australia

[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Natl Ctr Infect Canc, Melbourne, Vic, Australia

[3] Murdoch Childrens Res Inst, Parkville, Vic, Australia

[4] Royal Childrens Hosp, Dept Infect Dis, Melbourne, Vic, Australia

[5] Peter MacCallum Canc Ctr, Dept Clin Haematol, Melbourne, Vic, Australia

[6] Royal Melbourne Hosp, Melbourne, Vic, Australia

[7] Univ Melbourne, Dept Med, Parkville, Vic, Australia

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2021年 / 19卷 / 06期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

CAR-T cell therapy; infection; antimicrobial prophylaxis; hematological malignancy; infection prevention;

D O I：

10.1080/14787210.2021.1855143

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Introduction: Chimeric antigen receptor T-cell therapy (CAR-T cell therapy) is a novel immunotherapy with promising results in the treatment of relapsed or refractory B cell malignancies. Patients undergoing CAR-T cell therapy are at increased risk of infection due to prior immunosuppression, lymphodepleting chemotherapy, treatment of unique toxicities with tocilizumab and/or steroids, on-target effects of hypogammaglobulinaemia, and prolonged cytopenias. Areas covered: A narrative review of infections (PubMed, August 2020) occurring in patients undergoing CAR-T cell therapy is described, and the evidence for infection prevention strategies is presented. Expert commentary: The rapid adoption of CAR-T cell therapy into clinical practice presents many challenges for the diagnosis, management, and prevention of infection. Ongoing surveillance of the spectrum of infectious complications and effectiveness of prophylaxis is required to support safe and effective patient care.

引用

页码：749 / 758

页数：10

共 51 条

[1] Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma [J].

Abramson, Jeremy S. ;

Irwin, Kelly E. ;

Frigault, Matthew J. ;

Dietrich, Jorg ;

McGree, Brianne ;

Jordan, Justin T. ;

Yee, Andrew J. ;

Chen, Yi-Bin ;

Raje, Noopur S. ;

Barnes, Jeffrey A. ;

Davis, Benjamin .

CANCER, 2019, 125 (21) :3692-3698

[2] The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma [J].

Ali, Sahra ;

Kjeken, Rune ;

Niederlaender, Christiane ;

Markey, Greg ;

Saunders, Therese S. ;

Opsata, Mona ;

Moltu, Kristine ;

Bremnes, Bjorn ;

Gronevik, Eirik ;

Muusse, Martine ;

Hakonsen, Gro D. ;

Skibeli, Venke ;

Kalland, Maria Elisabeth ;

Wang, Ingrid ;

Buajordet, Ingebjorg ;

Urbaniak, Ania ;

Johnston, John ;

Rantell, Khadija ;

Kerwash, Essam ;

Schuessler-Lenz, Martina ;

Salmonson, Tomas ;

Bergh, Jonas ;

Gisselbrecht, Christian ;

Tzogani, Kyriaki ;

Papadouli, Irene ;

Pignatti, Francesco .

ONCOLOGIST, 2020, 25 (02) :E321-E327

[3]

[Anonymous], [No title captured]

[4]

Ariza-Heredia EJ, 2017, DIAGN MICROBIOL INFE, P88

[5] Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy [J].

Bhoj, Vijay G. ;

Arhontoulis, Dimitrios ;

Wertheim, Gerald ;

Capobianchi, James ;

Callahan, Colleen A. ;

Ellebrecht, Christoph T. ;

Obstfeld, Amrom E. ;

Lacey, Simon F. ;

Melenhorst, Jan J. ;

Nazimuddin, Farzana ;

Hwang, Wei-Ting ;

Maude, Shannon L. ;

Wasik, Mariusz A. ;

Bagg, Adam ;

Schuster, Stephen ;

Feldman, Michael D. ;

Porter, David L. ;

Grupp, Stephen A. ;

June, Carl H. ;

Milone, Michael C. .

BLOOD, 2016, 128 (03) :360-370

[6] T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial [J].

Brudno, Jennifer N. ;

Shi, Victoria ;

Stroncek, David ;

Pittaluga, Stefania ;

Kanakry, Jennifer A. ;

Curtis, Lauren M. ;

Gea-Banacloche, Juan C. ;

Pavletic, Steven ;

Bagheri, Mohammad-Hadi ;

Rose, Jeremy J. ;

Patel, Rashmika ;

Hansen, Brenna ;

Gress, Ronald E. ;

Kochenderfer, James N. .

BLOOD, 2016, 128 (22)

[7] Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study [J].

Budde, Lihua E. ;

Sehn, Laurie H. ;

Assouline, Sarit ;

Flinn, Ian W. ;

Isufi, Iris ;

Yoon, Sung-Soo ;

Kim, Won-Seog ;

Matasar, Matthew J. ;

Nastoupil, Loretta J. ;

Santiago, Raoul ;

Koh, Youngil ;

Hernandez, Genevive ;

Li, Chi-Chung ;

Kulkarni, Priya R. ;

McCall, Bruce ;

McClellan, Scott ;

Yin, Shen ;

Gupta, Vinita ;

Chu, Yu-Waye ;

Bartlett, Nancy L. .

BLOOD, 2018, 132

[8]

Cheson BD, 1995, JCO, V13

[9] Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells [J].

Cordeiro, Ana ;

Bezerra, Evandro D. ;

Hirayama, Alexandre V. ;

Hill, Joshua A. ;

Wu, Qian V. ;

Voutsinas, Jenna ;

Sorror, Mohamed L. ;

Turtle, Cameron J. ;

Maloney, David G. ;

Bar, Merav .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (01) :26-33

[10] Late Effects of CD19-Targeted CAR-T Cell Therapy [J].

Cordeiro, Ana ;

Bezerra, Evandro D. ;

Hill, Joshua Aiden ;

Turtle, Cameron J. ;

Maloney, David G. ;

Bar, Merav .

BLOOD, 2018, 132

← 1 2 3 4 5 6 →